3 unknown, 1 recruiting, 1 terminated. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Unknown 3, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Camurati-Engelmann Syndrome: new trials by email Literature Review of Camurati-Engelmann Syndrome trials Research Report on Camurati-Engelmann Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Bicara Therapeutics | 650 | 2025-01-28 | 2026-10-29 |
| Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis Pioglitazone 30mg, Empagliflozin 10 MG - Non Alcoholic Steatohepatitis | Phase 3 | Unknown | Tanta University | 56 | 2022-11-01 | 2022-11-04 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| Study of Arimidex and Radiotherapy Sequencing Pre-radiotherapy commencement of Arimidex, Post radiotherapy commencement of Arimidex, Radiotherapy - Breast Cancer | Phase 3 | Unknown | Fudan University | 220 | 2011-07-01 | 2014-06-25 |
| Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients Losartan and nebivolol, Losartan, Nebivolol - Marfan Syndrome | Phase 3 | Unknown | Fondazione IRCCS Policlinico San Matteo di Pavia | 291 | 2008-07-01 | 2011-07-22 |
Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Marfan Syndrome (1) · Non-alcoholic Fatty Liver Disease (1) · Squamous Cell Carcinoma of Head and Neck (1)
Bone Diseases (5) · Bone Diseases, Developmental (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Musculoskeletal Diseases (5) · Osteochondrodysplasias (5) · Neoplasms (3) · Neoplasms by Site (3) · Carcinoma (2) · Digestive System Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Skin and Connective Tissue Diseases (2) · Abnormalities, Multiple (1) · Adenocarcinoma (1)
Anastrozole (1) · Cisplatin (1) · Gemcitabine (1) · Losartan (1) · Nebivolol (1) · Pioglitazone (1) · Radiotherapy (1) · empagliflozin (1) · pembrolizumab (1)
Bicara Therapeutics (1) · EMD Serono Research & Development Institute, Inc. (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Fudan University (1) · Tanta University (1)
Italy (3) · Argentina (2) · Australia (2) · Brazil (2) · China (2) · France (2) · Germany (2) · Japan (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · United States (2) · Austria (1)
Eloisa Arbustini, MD,FESC,FACC (1) · Jiayi Chen, MD (1) · Luigi Tavazzi, MD,FESC,FACC (1)
PMID 16601194, PMID 17188619, PMID 17911499, PMID 19430350, PMID 32461347, PMID 38875119
2019 (1)